Investigational Drug Information for AZD-1981
✉ Email this page to a colleague
What is the development status for investigational drug AZD-1981?
AZD-1981 is an investigational drug.
There have been 32 clinical trials for AZD-1981.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 15th 2021.
The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Adenocarcinoma. The leading clinical trial sponsors are AstraZeneca, Samsung Medical Center, and National Cancer Institute (NCI).
There are eight US patents protecting this investigational drug and two hundred and forty-one international patents.
Summary for AZD-1981
| US Patents | 8 |
| International Patents | 241 |
| US Patent Applications | 51 |
| WIPO Patent Applications | 13 |
| Japanese Patent Applications | 10 |
| Clinical Trial Progress | Phase 3 (2021-09-15) |
| Vendors | 56 |
Recent Clinical Trials for AZD-1981
| Title | Sponsor | Phase |
|---|---|---|
| Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2 | AstraZeneca | Phase 3 |
| Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2 | Botswana Ministry of Health | Phase 3 |
| Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2 | Botswana Harvard AIDS Institute Partnership | Phase 3 |
Clinical Trial Summary for AZD-1981
Top disease conditions for AZD-1981
Top clinical trial sponsors for AZD-1981
US Patents for AZD-1981
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AZD-1981 | ⤷ Try a Trial | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Try a Trial |
| AZD-1981 | ⤷ Try a Trial | Chemical compounds | AstraZeneca AB (Sodertalje, SE) | ⤷ Try a Trial |
| AZD-1981 | ⤷ Try a Trial | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Try a Trial |
| AZD-1981 | ⤷ Try a Trial | Substituted pyridinyl-pyrimidines and their use as medicaments | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) | ⤷ Try a Trial |
| AZD-1981 | ⤷ Try a Trial | Pyrrolotriazinone derivatives as PI3K inhibitors | Almirall, S.A. (Barcelona, ES) | ⤷ Try a Trial |
| AZD-1981 | ⤷ Try a Trial | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | AstraZeneca AB (Sodertalje, SE) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AZD-1981
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AZD-1981 | Argentina | AR099177 | 2034-01-24 | ⤷ Try a Trial |
| AZD-1981 | Australia | AU2015208932 | 2034-01-24 | ⤷ Try a Trial |
| AZD-1981 | Australia | AU2017200338 | 2034-01-24 | ⤷ Try a Trial |
| AZD-1981 | Australia | AU2018202956 | 2034-01-24 | ⤷ Try a Trial |
| AZD-1981 | Australia | AU2019202675 | 2034-01-24 | ⤷ Try a Trial |
| AZD-1981 | Canada | CA2935625 | 2034-01-24 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
